These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21168673)

  • 1. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.
    Doesch AO; Mueller S; Konstandin M; Celik S; Erbel C; Kristen A; Frankenstein L; Koch A; Dengler TJ; Ehlermann P; Zugck C; De Geest S; Katus HA
    Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients.
    Dumortier J; Guillaud O; Boillot O
    Liver Transpl; 2013 May; 19(5):529-33. PubMed ID: 23483701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M; Rivinius R; Ruhparwar A; Schmack B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Ehlermann P; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2015; 9():1217-24. PubMed ID: 25759566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Outcome of renal transplantation after tacrolimus switch to cyclosporine].
    Mesar I; Basić-Jukić N; Bubić-Filipi L; Kastelan Z; Bacak-Kocman I; Kes P
    Acta Med Croatica; 2011; 65(4):311-4. PubMed ID: 22359902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population.
    Chen YB; Li SD; Ju BL; Shi XJ; Lu F; Hu DK; Yu CH; Dong JH
    Transplant Proc; 2011 Jun; 43(5):1751-3. PubMed ID: 21693271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitors in heart transplantation.
    Keogh A
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily prolonged-release tacrolimus in de novo liver transplantation: a single center cohort study.
    Marubashi S; Wada H; Kobayashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Hepatogastroenterology; 2012 Jun; 59(116):1184-8. PubMed ID: 22172333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.